Search

Karyopharm Therapeutics Inc

Cerrado

SectorSanidad

1.87 -3.61

Resumen

Variación precio

24h

Actual

Mínimo

1.92

Máximo

1.96

Métricas clave

By Trading Economics

Ingresos

-45M

-67M

Ventas

-1.6M

33M

BPA

-2.32

Margen de beneficios

-200.476

Empleados

228

EBITDA

19M

9.5M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+269.9% upside

Dividendos

By Acuity

Próximas Ganancias

2 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-3.4M

41M

Apertura anterior

5.48

Cierre anterior

1.87

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

147 / 340 Clasificación en Healthcare

Karyopharm Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 ago 2026, 23:51 UTC

Karyopharm Therapeutics Inc shares are lower in after-market hours, following a brief uptick earlier. No specific news was identified to explain the decline.

20 ago 2026, 20:02 UTC

Karyopharm Therapeutics is declining sharply amid a significant downturn in the Biotechnology sub-sector, nearing the lower end of its one-month trading range.

18 ago 2026, 20:03 UTC

Karyopharm Therapeutics Inc is trading higher today, continuing its upward trend since Monday's close. The stock remains below its 20-day moving average.

17 ago 2026, 23:46 UTC

Karyopharm Therapeutics shares are higher in after-market hours, following volatility earlier. Broader market pressures include geopolitical tensions and rising crude oil prices.

14 ago 2026, 23:51 UTC

Karyopharm Therapeutics shares are higher in after-market trading, despite no specific news. Broader market sentiment reflects concerns from a decline in U.S. retail sales.

13 ago 2026, 23:11 UTC

Karyopharm Therapeutics Inc shares are rising in after-market trading, showing a modest upward trend since Thursday's close despite recent significant declines.

12 ago 2026, 19:56 UTC

Karyopharm Therapeutics Inc shares are lower today, retracing from an early high amid broader market conditions and geopolitical tensions. No specific news was identified.

11 ago 2026, 20:01 UTC

Karyopharm Therapeutics Inc is trading higher today, having reached a peak earlier in the session. The stock remains below its 20-day moving average.

10 ago 2026, 20:06 UTC

Karyopharm Therapeutics Inc shares are lower today, reversing an early gain and reaching a mid-morning low, with no specific news identified for the decline.

7 ago 2026, 23:31 UTC

Karyopharm Therapeutics shares are lower in after-market hours, following a decline earlier despite gains in major tech stocks. No specific news was identified.

6 ago 2026, 23:21 UTC

Karyopharm Therapeutics Inc shares are lower in after-market hours. The asset is trading below its 20-day moving average and near the lower end of its one-month range.

5 ago 2026, 23:01 UTC

Karyopharm Therapeutics shares are lower in after-market hours, continuing a three-session decline amid broader market weakness from disappointing U.S. employment data.

4 ago 2026, 23:46 UTC

Karyopharm Therapeutics shares are higher in after-market trading, though no specific news explains the movement. Broader market optimism may be influencing risk assets.

3 ago 2026, 23:41 UTC

News

Karyopharm Therapeutics shares are lower in after-market hours following the grant of restricted stock units to a new employee, raising potential dilution concerns.

1 ago 2026, 00:01 UTC

Karyopharm Therapeutics Inc shares are higher in after-market hours, reaching their highest cumulative return of the day despite recent underperformance.

31 jul 2026, 23:31 UTC

Karyopharm Therapeutics shares rose during after-market hours, continuing a recovery from an earlier low. The stock remains below its 20-day moving average.

30 jul 2026, 23:41 UTC

Social Media
Event
News

Karyopharm Therapeutics shares fell sharply after its Phase 3 trial for selinexor failed to meet key endpoints, leading to a shift in focus away from endometrial cancer.

29 jul 2026, 19:27 UTC

Macro Event

Karyopharm Therapeutics shares are lower as investor anxiety rises following the Federal Reserve's decision to maintain interest rates amid global uncertainties.

27 jul 2026, 19:07 UTC

Karyopharm Therapeutics Inc shares are lower during Monday's trading session, reflecting ongoing weakness and broader market trends amid declining crude oil prices.

24 jul 2026, 19:42 UTC

Karyopharm Therapeutics Inc. shares are higher during Friday's session, continuing a notable advance since Thursday, despite broader market challenges.

23 jul 2026, 09:01 UTC

Karyopharm Therapeutics Inc shares are higher in pre-market trading, continuing an upward trend since Wednesday, despite recent volatility and no specific news.

22 jul 2026, 18:41 UTC

Social Media

Karyopharm Therapeutics shares are declining amid market caution and rising crude oil prices. RBC Capital reaffirmed its Outperform rating with a $16 price target.

21 jul 2026, 20:12 UTC

Karyopharm Therapeutics shares are lower in after-market hours, with no specific news driving the decline despite positive sentiment in U.S. markets.

20 jul 2026, 23:01 UTC

News

Karyopharm Therapeutics shares fell in after-market hours following the announcement of a leadership cash retention program aimed at key executives.

Comparación entre iguales

Cambio de precio

Karyopharm Therapeutics Inc previsión

Precio Objetivo

By TipRanks

269.9% repunte

Estimación a 12 Meses

Media 7.25 USD  269.9%

Máximo 11 USD

Mínimo 3 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Karyopharm Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

3

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

147 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$